One Sentence Summary: Analyses of cardiomyocytes with hypertrophic cardiomyopathy mutations in MYBPC3 reveal that these directly activate myosin contraction by disrupting myosin states of relaxation, and that genetic or pharmacological manipulation of myosin therapeutically abates the effects of MYBPC3 mutations.
Introduction
Hypertrophic cardiomyopathy (HCM) is a heritable disease of heart muscle affecting ~ 1 in 500 1 individuals. Patient symptoms can be minimal or relentlessly progressive with resultant heart failure and/or sudden cardiac death 2 . Adverse clinical outcomes in HCM increase with disease duration, thereby underscoring the importance of therapeutic strategies to abate disease progression 3 .
Dominant pathogenic variants in eight sarcomere genes cause HCM, but predominate in MYBPC3 and MYH7 (encoding β cardiac myosin heavy chain; β-MHC) 4 . The overwhelming majority of HCM founder mutations [5] [6] [7] [8] [9] [10] [11] , including one affecting 4% of South Asians 12 reside in MYBPC3. All HCM mutations in MYH7 encode missense substitutions 4 and mutant myosins are incorporated into the sarcomere. By contrast, most MYBPC3 mutations are truncating and are predicted to cause haploinsufficiency of cMyBPC 13, 14 . The mechanisms by which distinctive mutations in these two sarcomere proteins uniformly produce hyperdynamic contraction and poor relaxation (diastolic dysfunction) in advance of the morphologic remodelling in HCM [15] [16] [17] remain incompletely understood 18 .
Biophysical analyses demonstrate that HCM mutations in β-MHC, the molecular motor of the sarcomere, increase ATPase activity, actin-sliding velocity, and power (reviewed 19 ). Structural data also predict that MYH7 mutations disrupt dynamic conformational interactions that occur between paired myosin molecules during relaxation 20 . These are denoted as i) disordered relaxation (DRX), a state where one or both myosin heads could be active, able to hydrolyse ATP and potentiate force; and ii) super relaxation (SRX), a state of dual inactivation of myosins with both ATPases inhibited. cMyBPC has structural and functional roles in sarcomere biology 21 . cMyBPC is generally thought to serve as a brake that limits cross bridge interactions 21 through its biophysical interactions of its amino and carboxyl termini with both myosin 22 and actin 23 . Phosphorylation of the amino terminus of cMyBPC reduces myosin and increase actin interactions to promote cross-bridge formation 22 , events that are reversed by calcium levels that maximally activate thin filaments 23, 24 . Interpreting these interactions in the context of HCM mutations that reduce cMyBPC levels is complex for several reasons. Cardiac histopathology and in vivo function of heterozygous Mybpc3 +/mice, which genetically recapitulate human HCM mutations, are indistinguishable from wildtype. Homozygous loss of cMyBPC impairs developmental cytokinesis resulting in expansion of mononuclear cardiomyocytes 25 and cardiac function that mimics cMyBPC phosphorylation, with increased contractile force 23, 26 . Recent studies also demonstrate that loss of cMyBPC also alter proportions of relaxed myosin in DRX and SRX conformations 27, 28 , but whether or not this relates to contractility is unknown.
To better understand how MYBPC3 mutations cause HCM, we assessed sarcomere function in the setting of cMyBPC deficiency and genetically altered myosin or pharmacologic attenuation of myosin ATPase activity. In combination, these assays shed light on unifying mechanisms that drive HCM pathophysiology and demonstrate that a single pharmacologic manipulation of myosin corrects sarcomere dysfunction caused by MYBPC3 mutations, thereby providing a promising avenue for treating this prevalent cause of human HCM.
Results
We studied three mouse models with altered cMyBPC expression (Supplemental Figure  1 ). Mybpc3 t/+ and Mybpc3 t/t mice carry endogenous heterozygous or homozygous truncating mutations 29, 30 and express graded reductions of cMyBPC protein. MyBPC-RNAi 25 are wildtype (WT) mice transfected (P10) with a cardiotropic adeno-associated (serotype 9) virus carrying green fluorescent protein (GFP) and RNAi targeting Mybpc3 transcripts. Injection of 5 x 10 11 viral genomes (vg)/kg reduced Mybpc3 transcripts to less than 10% of levels in WT mice and abolished protein expression ( Supplemental Figures 1-3 ). Sham-RNAi +/-denotes Mybpc3 t /+ mice transfected with virus carry GFP alone. We also studied heterozygous (Myh6 F764L/+ ) and homozygous (Myh6 F764L/ F764L ) mice, which mimic a human MYH7 mutation that causes dilated cardiomyopathy (DCM). 31, 32 
In vivo cardiac phenotypes in Mypbc3 mutant mice
Previous studies demonstrate that Mybpc3 t/+ mice have normal contractility and morphology, but with increased load Mybpc3 t/+ mice develop greater left ventricular hypertrophy than WT mice 29, 33 . Mybpc3 t/t mice have significantly increased LV volumes and hypertrophy (increased LV wall thickness; LVWT) due in part to increased numbers of cardiomyocytes from additional perinatal divisions prior to permanent exit from the cell cycle. 25 By contrast, MyBPC-RNAi mice developed progressive hypertrophy in comparison WT (Supplemental Figure 2A -C) similar to other HCM mice 25 , without changes in ventricular volumes. Fractional shortening, an in vivo measure of contractility, was not significantly different between MyBPC-RNAi and WT mice.
Contractility and Relaxation in Cardiomyocytes from Mypbc3 Mutant Mice.
As in vivo contractility and relaxation reflects sarcomere performance as well as myocardial geometry, histopathology, and hemodynamic load, we studied ex vivo cardiomyocytes to assess biophysical functions of sarcomeres with altered cMyBPC levels. Isolated cardiomyocytes from at least four mice of each genotype (cells numbers indicated in figure legends) were studied. Sarcomere length was measured throughout the contractile cycle to assess cellular shortening, a surrogate systolic function ( Figure 1A -D). Cardiomyocytes isolated from naïve or sham-RNAi +/-mice had comparable cell shortening thereby excluding an effect of AAV9 on contractility (Supplemental Figure 2D ). Cardiomyocytes with altered cMyBPC expression had dosage-dependent increases in maximal cellular shortening ( Figure 1C ). In comparison to WT, Mybpc3 t/+ cardiomyocytes had 50% increased shortening (7.2 ± 0.25% p < 0.03), whilst cellular shortening was increased by 100% in cardiomyocytes lacking cMyBPC (MyBPC-RNAi: 10 ± 0.6%; Mybpc3 t/t: 9.5 ± 0.9%; p<0.0001). Notably, augmentation of cellular shortening of isolated cardiomyocytes with cMyBPC deficiency did not result in increased contractility in vivo, 25, 29 an observation that implies additional (biochemical, transcriptional, and morphologic) processes can modulate ensemble systolic performance of cardiomyocytes.
Human HCM is characterized by impaired diastolic performance, a parameter that is difficult to assess in mice. However, tracking sarcomere lengths in isolated cardiomyocytes across the contractile cycle provided a quantitative proxy for diastolic function, the duration of relaxation ( Figure 1D ). Relaxation was prolonged in MyBPC-RNAi and Mybpc3 t/t cardiomyocytes (0.31 ± 0.02; p < 0.0001 and 0.38 ± 0.06; p < 0.0056) compared to WT cells (0.21 ± 0.02), while the duration of relaxation in Mybpc3 t/+ cardiomyocytes was indistinguishable from WT (0.19 ± 0.02).
Genetic Repression of Myosin Function Corrects cMyBPC Deficiency
Rare myosin missense mutations cause DCM, a disorder characterized by ventricular enlargement and diminished cardiac contractility Mice engineered to carry the human DCM mutation Myh6 F764L/+ and Myh6 F764L/ F764L mice recapitulate these phenotypes. 31 Analyses of isolated cardiomyocytes from these models showed a genotype-dependent depressed cellular shortening ( Figure 2A ): contractility in Myh6 F764L/+ and Myh6 F764L/ F764L cardiomyocytes was 75% and 50% of normal (P < 0.0001 for each). DCM cardiomyocytes also had small, but significantly reduced durations of relaxation ( Figure 2B ) (Myh6 F764L/+ : 0.17 ± 0.01, p = 0.0002; Myh6 F764L/ F764L : 0.14 ± 0.005, p < 0.0001) compared to WT cardiomyocytes (0.21 ± 0.02).
To determine if manipulation of myosin properties would alter hyper-contractility of Mybpc3 mutations, we injected AAV9 carrying GFP and MyBPC-RNAi into P10 Myh6 F764L/ F764L mice. Forty days post injection the cellular shortening ( Figure 2A ) and duration of relaxation ( Figure 2B ) were significantly improved in comparison to MyBPC-RNAi cardiomyocytes (p<0.0001) and both contractile and relaxation parameters were indistinguishable from WT cardiomyocytes.
Inhibition of Myosin ATPase Corrects cMyBPC Defects in Cardiomyocytes and Cardiac Tissues
As genetic deficits in myosin normalized the performance of Mybc3-deficient cardiomyocytes, we tested the hypothesis that MYK-461, a cardiac-selective, pharmacologic allosteric myosin ATPase inhibitor, would also be effective. Acute treatment of Mypbc3 t/+ and Mypbc3 t/t cardiomyocytes with MYK-461 reduced the hyper-contractility in a dose dependent manner ( Figure 2C ). Contractile function was normalized in Mypbc3 t/+ cardiomyocytes at 0.15 µM MYK-461 and in Mypbc3 t/t dosages at ~ 0.3 µM. The higher dose of MYK-461 reduced sarcomere contractility by ~50% in both mutant genotypes and depressed contractility by ~30% in WT cardiomyocytes. Concurrently, 0.3 µM of MYK-461 normalized relaxation times in Mypbc3 t/t cardiomyocytes ( Figure 2D ), but did not alter the duration of relaxation in Mypbc3 t/+ or WT cardiomyocytes.
Increased Ratios of Myosin Heads in DRX:SRX caused by cMyBPC-deficiency are Normalized by Modulation of Myosin ATPase.
The proportions of myosin heads in DRX and SRX conformations correlate with the rate of ATP cycling in relaxed muscle, which can be measured by the decay of a fluorescent, nonhydrolyzable ATP (Mant-ATP) from skinned muscle 34 or cell fibers. (Figure 3 and Supplemental Figure 4 ). Myosin heads in the DRX configuration have ~5x more ATPase activity than myosin heads in the SRX configuration 34 . Hence the fraction of myosin heads in the SRX configuration and DRX configuration can be estimated from the fraction of Mant-ATP that is released rapidly (DRX) or slowly (SRX).
Assays of skinned cardiac fibers from WT, Mypbc3 t/+ and Mypbc3 t/t mice showed significantly different proportions of myosins in DRX and SRX confirmations (Figure 3 A-C). Compared to WT cardiac tissues, Mypbc3 t/+ and Mypbc3 t/t had a 12% shift (p = 0.0274) and 23% shift (p = 0.0002), respectively, of myosins in DRX ( Figure 3B ), changes that paralleled the dose-dependent increase in cardiomyocyte contractility ( Figure 1C ). By contrast, assessment of the proportions of SRX and DRX found in Myh6 F764L/+ and Myh6 F764L/ F764L were comparable to those of wildtype mice, a finding that indicates that this DCM mutation should impact only contractility with minimal impact on cardiomyocyte relaxation (Supplemental Figure 5 ).
As an allosteric inhibitor of myosin ATPase, we asked if MYK-461 would also alter the fraction of myosin heads in the SRX and DRX configuration in cardiac tissues from WT and cMyBPC-deficient mice. MYK-461 (0.3 µM) treatment of skinned cardiac fibers (Figure 3 A-C) increased the proportion of myosins in SRX and reduced myosins in DRX by 15% in WT (p = 0.007), 20% in Mypbc3 t/+ (p = 0.001) and by 26% in Mypbc3 t/t fibers (p = 0.0009) in comparison to untreated corresponding genotypes. Notably this MYK-461 dose normalized cardiomyocyte contractility ( Figure 2C,D) , indicating a direct relationship between the proportion of myosins in DRX and cellular hyper-contractility.
Analyses of Mant-ATP release from skinned human heart fibers with heterozygous MYBPC3 truncations showed abnormalities comparable to those in mutant mouse hearts. The proportion of myosin in DRX was increased (~12%, p = 0.0031) compared to normal human heart fibers (Figure 3 D-F). Moreover, treatment of MYBPC3-deficient fibers with 0.3 µM MYK-461 normalized the ratio of DRX/SRX, by reciprocally reducing the proportion in DRX and increasing the proportion in SRX by 16% (p = 0.0022, vs. untreated).
Taken together, these observations indicate that MYBPC3 mutations in humans and mice disrupt normal myosin conformations, resulting in the increased contractility and ATP consumption associated with HCM. These abnormalities can be pharmacologically corrected with the myosin ATPase inhibitor, MYK-461.
Discussion
Truncating mutations in Mybpc3 and RNAi knockdown of cMyBPC levels caused comparable abnormalities in cardiomyocyte contraction and relaxation, supporting the conclusion that MYBPC3 mutations cause HCM by haploinsufficiency. We show that the severity of cardiomyocyte phenotypes is dependent on cMyBPC levels; truncation of one allele caused milder abnormalities in systolic and diastolic performance than biallelic mutations. The phenotypes of MyBPC-RNAi cardiomyocytes confirmed this dose-dependent relationship; extinguishing post-natal protein expression substantially amplified hypercontractility and impaired relaxation, evidencing a direct role of cMyBPC across the cardiac cycle.
We show that the MYBPC3 mutations directly alter myosin biophysical properties (Figure 4 ). Genetic repression of myosin's motor function, as occurs in Myh6 764/764 cardiomyocytes, 31 normalized the hypercontractile phenotype of cMyBPC deficiency, a finding that centrally positions myosin dysregulation as the mechanism for the pathogenicity of cMyBPC mutations. These observations also indicate that strategies to reduce cMyBPC levels can, at least transiently, increase myosin contractility. A second, pharmacological approach to depress myosin function confirmed the conclusion that myosin dysregulation is a unifying mechanism in HCM and indicated the therapeutic potential of targeting myosin in patients with MYBPC3 mutations as a novel treatment for cMyBPC truncation. As previously shown in HCM mice with myosin mutations 3 , MYK-461-treatment of mouse or human heart tissues with cMyBPC mutations resulted in dose-dependent attenuation of hypercontractility.
Earlier studies of Mypbc3 t/t mice using in vivo echocardiography or invasive hemodynamic assessments identified reduced systolic contraction, quite unlike the prominent hypercontractility observed in isolated Mypbc3 t/t or MyBPC-RNAi cardiomyocytes. Several factors may account for these dichotomous findings. Mypbc3 t/t cardiomyocytes have impaired post-natal cytokinesis that increases numbers of cardiomyocytes, particularly mononuclear cardiomyocytes 25 that may be dysfunctional. Increased mononuclear cells, hypercontractility of binuclear cells, and altered myocardial geometry may each increase energy demands, which when unmet, could compromise contraction, promote cardiomyocyte death, and increase myocardial fibrosis that is prominent in Mypbc3 t/t hearts. By eliminating these factors, our analyses of isolated Mypbc3 t/t and post-natal MyBPC-RNAi cardiomyocytes provided a more proximal readout, revealing that reduced cMyBPC levels increased sarcomere contractility. cMyBPC deficiency also altered cardiac relaxation. Although we could not demonstrate significant relaxation deficits in Mypbc3 t/+ cardiomyocytes, similar to the normal findings of Mypbc3 t/+ cardiac fibers, 27, 28 diastolic abnormalities are evident in clinical studies of patients with heterozygous MYPBC3 mutations 29 and prominent in Mypbc3 t/t cardiomyocytes. Both Myh6 764/764 and MYK-461 abrogated increased relaxation durations associated with cMyBPC deficiency, further strengthening the conclusion that myosin dysregulation is the central driver of HCM pathophysiology, in which diastolic dysfunction predominates.
Mant-ATP experiments provided a mechanism for relaxation abnormalities. Our experiments and those by others 27, 28 show altered proportions of myosins in DRX and SRX in mouse and human myocardium with truncating cMyBPC mutations. Loss of cMyBPC increased the proportions of myosin in the more active DRX conformation. Importantly, MYK-461 restored physiologic DRX/SRX proportions in mice and human tissues, at concentrations that alleviated enhanced cardiomyocyte contractility, data that strongly suggests that increases in the proportion of myosins in DRX contributes to the hyper-contractile phenotype of HCM. As MYK-461 was acutely administered to permeabilized myocardium in our study, its binding to myosin (and not secondary signalling events) is most likely the driver of these beneficial biophysical changes. We therefore suggest that MYK-461 represses filamentous function by directly decreasing myosin contractile function and increasing relaxation properties, providing evidence for dual mechanisms by which MYK-461 can modulate muscle function. These preclinical data, reinforced by the data from human myocardium of patients with Mybpc3 mutations, indicate the potential for MYK-461 to benefit HCM patients with cMyBPC as well as with myosin mutations. 3 In summation, cMyBPC truncation drives disease by a mechanism of haploinsufficiency, wherein myosin SRX conformations are destabilized, leading to deleterious levels of DRX that drive hyper-contractility, impair relaxation, and increase energy consumption. This triad of abnormalities accurately explains the clinical phenotypes of hyper-dynamic contraction, diastolic dysfunction, and energy deprivation in HCM hearts. By targeting myosin functions, genetically or pharmacologically, these phenotypes are normalized in cardiomyocytes and will likely reduce disease pathogenesis in vivo. Demonstrating that myosin is central to the pathophysiology of cMyBPC truncation, and extends the therapeutic utility of MYK-461 to the proportionally largest subset of HCM patients with MYBPC3 mutations.
Materials and Methods

MyBP-C truncation
All animal protocols were compliant with the approved protocols of the Association for the Assessment and Accreditation of Laboratory Animal Care and Harvard Medical School. Mypbc3 t/+ , Mypbc3 t/t and WT mice were studied (129SvEv background) with histopathology being previously described in detail 23, 29 . The truncated Mybpc3 alleles were created by PGKneomycin resistance gene insertion into exon 30 creating a predicted truncation at amino acid 1,064 of the 1,270 residues of cMyBPC. The homozygous truncated allele has been shown to produce less than 10% of normal cMyBPC. It should be noted that a greater proportion of cells in the Mypbc3 t/t cohort exhibited fibrillation and were excluded from contractile measures as they could not be reliably paced, making measures in Mypbc3 t/t cardiomyocytes more challenging.
RNAi
RNAi was delivered at P10 by AAV vector using AAV9 capsid packaging by triple transfection as described 25 . The AAV9 vector contains an shRNA construct that specifically targets specific 21-base-pair sequence targeted to Mybpc3 exon19 and an enhanced GFP plasmid (Addgene). Vector was injected into the thoracic cavity of P1 t/+ neonates [5 x 10 13 viral genomes (vg)/kg], GFP fluorescence was used to identify isolated cardiomyocytes that had taken up the vector. GFP fluorescence was evident from 48 hours post-injection for at least 5 months, RNAi reduced cMyBPC expression to ~10% of normal 25 .
Human myectomy samples
Human myectomy samples were obtained after written informed consent from three HCM patients with distinct heterozygous frameshift truncating variants (Gln981fs, Leu1014fs, and Lys1209fs) in MYBPC3. Myectomy samples of the septum were flash frozen and stored in liquid nitrogen and tissue preparation for Mant-ATP experiments were performed as described below.
Myocyte isolation
Cardiomyocytes were isolated from 8-20 week old mice by rapid explantation and aortic cannulation on a Langendorff apparatus for perfusion with Enzyme Buffer (EB composition: 135 mM NaCl, 4 mM KCl, 0.33 mM NaH 2 PO 4 , 1 mM MgCl 2 , and 10 mM HEPES, pH 7.40, which incorporated Collagenase D, Collagenase B and Protease XIV) for 10 minutes. After perfusion the atria and right ventricle were removed and the left ventricle was minced in TA buffer (Composition: 135 mM NaCl, 4 mM KCl, 0.33 mM NaH 2 PO 4 , 1 mM MgCl 2 , and 10 mM HEPES, pH 7.40, which incorporated bovine serum albumin) and passed through a 100 µm filter into a 50ml conical tube. Tissue settled for 15 minutes to allow myocytes to pellet by gravity. The pellet was then sequentially resuspended every 10 minutes through an increasing calcium gradient (5%, 20%, 50%, 100% calcium tyrode) to provide a cell fraction enriched in myocytes with a final experimental buffer (Composition: NaCl 137 mM, KCl 5.4 mM, CaCl 2 1.2 mM, MgCl 2 0.5 mM, HEPES 10 mM at pH 7.4, which incorporated glucose).
Contractile measures of myocyte function
Isolated cardiomyocytes were placed in wells of a 6-well plate that had been precoated with laminin. Laminin coating was performed for two hours before cardiomyocyte introduction at a concentration of 10 ug/mL in PBS (Composition: KH 2 PO 4 1mM, NaCl 155 mM, Na 2 HPO 4 3mM, at pH 7.4). Laminin coating solution was washed once with PBS before cells were introduced into the wells. Once cells were introduced they were left to incubate for 10 minutes to equilibrate to experimental temperature (30°C). Cells were imaged using a Keyence BZ-X710 microscope using a Nikon 40X/0.65 NA objective. Cells were kept at 30°C using microscope specific incubation chamber that was also used to deliver 20% O 2 and 5% CO 2 to the experimental chamber. Cells were paced at 1Hz using custom-built electrodes hooked up to a pacing unit (Pulsar 6i, FHC Brunswick, ME, USA) delivering 20V. Movies were acquired at 29 frames per second for 5 seconds (5 contractile cycles).
An ImageJ plugin SarCoptiM was used to track sarcomere lengths during contractile cycles 35 . Sarcomere tracking was then used to calculate cellular shortening (%), relaxed and contracted sarcomere lengths (µm), contractile cycle and relaxation durations (seconds).
For experiments incorporating MYK-461, drug was applied in concentrations ranging 0.05 -0.3 µM in the experimental buffer. MYK-461 was incubated with cells for a minimum of 10 minutes before data acquisition.
Mant-ATP experiments
Mice were sacrificed by rapid cervical dislocation, atria and right ventricle were removed and samples were flash frozen in liquid nitrogen. Mant-ATP protocols were adapted from publications 27, 34 : 20 mg left ventricular human or mouse myocardial samples were thawed in permeabilization buffer (Composition: NaCl 100 mM, MgCl 2 8 mM, EGTA 5 mM, K 2 HPO 4 5 mM, KH 2 PO 4 5 mM, NaN 3 3 mM, ATP 5 mM, DTT 1 mM, BDM 20 mM, Triton-X 100 0.1%, at pH 7.0). Samples were permeabilized for 6 hours on ice on a rocker solution changes occurring every two hours. At the completion of this step samples were stored overnight at -20°C in glycerinating solution (Composition: K acetate, 120 mM; Mg acetate, 5 mM; K 2 HPO 4 , 2.5 mM; KH 2 PO 4 , 2.5 mM; MOPS, 50 mM; ATP, 5 mM; BDM, 20 mM; DTT, 2 mM; glycerol, 50% (v/v), pH 6.8.) for dissection within 2 days.
Once glycerinated ventricular myocardium was dissected into ~ 90 x 400 µm pieces that were held under two pins in a chamber constructed from a slide and coverslip. These samples were permeabilized using the permeabilization buffer for a further 30 minutes on ice prior to experimentation. After secondary permeabilization chambers were flushed with glycerinating buffer.
For fluorescence acquisition a Nikon TE2000-E was used with a Nikon 20X/0.45 objective, using a Hammamatsu C9100 EM-CCD. Frames were acquired every 10 seconds with a 20 ms acquisition and exposure time using a DAPI filter set, images were collected for 15 minutes. Prior to acquisition each chamber was flushed with ATP buffer (Composition: K acetate 120 mM, Mg acetate 5 mM, K 2 HPO 4 2.5 mM, KH 2 PO 4 2.5 mM, ATP 4 mM, MOPS 50 mM, DTT 2 mM at pH 6.8) to remove glycerol. This buffer was replaced with two chamber volumes of rigor buffer (Composition: K acetate 120 mM, Mg acetate 5 mM, K 2 HPO 4 2.5 mM, KH 2 PO 4 2.5 mM, MOPS 50 mM, DTT 2 mM at pH 6.8). Rigor buffer was incubated for 5 minutes to allow rigor to set in. 
Mant-ATP analysis
Similar to protocols previously described for analysis 27 three regions of each myocardial tissue strip were sampled for fluorescence decay using the ROI manager in ImageJ. The final data point of fluorescence wash in defined the y-intercept. All data was plot as a normalized intensity of initial fluorescent intensity from the three sampled regions. These data are fit to an unconstrained double exponential decay using Sigmaplot:
Where A1 is the amplitude of the initial rapid decay approximating the 'disordered relaxed state' (DRX) with T1 as the time constant for this decay. A2 is the slower second decay approximating the proportion of myosin heads in the 'super relaxed state' (SRX) with its associated time constant T2.
Each individual experiment was fit using this double exponential decay with all values determined and plot. Statistical analysis was performed using 2-way ANOVA with multiple comparisons tests.
Statistics
Where appropriate students t-tests were employed. In instances where experimental hypothesis were tested amongst multiple treatment groups one-way analysis of variance (ANOVA) was used. For multiple comparisons post-hoc Bonferroni corrections were used with a significance cut off of p < 0.05.
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